Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab monotherapy and nivolumab + ipilimumab in pediatric high-grade primary CNS tumors
NL-OMON48940Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in brain cancer, Neuro-Oncological Malignancies, diffuse intrinsic pontine glioma (DIPG) and 6 more (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety and tolerability in safety lead-in, Overall survival in Cohort 1 and 4 more. Started Dec 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
brain cancerNeuro-Oncological Malignanciesdiffuse intrinsic pontine glioma (DIPG)gliomamedulloblastoma
Beyond the preview
Go deeper on NL-OMON48940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48940.